Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Long-term Prednisone Use for End-stage Heart Failure

Phase 2

Conditions: Heart Failure
Hyperuricemia

Interventions: Drug: prednisone

First Posted Date: 2014-11-04

Last Posted Date: 2017-01-12

Lead Sponsor: Hebei Medical University

Target Recruit Count: 90

Registration Number: NCT02282683

Locations: 🇨🇳
The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIL 284 BS
Drug: Placebo
Drug: Prednisone

First Posted Date: 2014-10-20

Last Posted Date: 2014-10-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02268149

Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate

Phase 2

Completed

Conditions: Prostate Adenocarcinoma
Prostate Cancer
High Risk Prostate Cancer

Interventions: Drug: Enzalutamide
Drug: Abiraterone Acetate
Drug: Prednisone
Drug: Leuprolide Acetate

First Posted Date: 2014-10-20

Last Posted Date: 2022-04-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 75

Registration Number: NCT02268175

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Theophylline and Steroids in Chronic Obstructive Pulmonary Disease (COPD) Study

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Placebo (for prednisone)
Drug: Theophylline
Drug: Placebo (for Theophylline)
Drug: Prednisone

First Posted Date: 2014-10-10

Last Posted Date: 2021-08-12

Lead Sponsor: The George Institute

Target Recruit Count: 1670

Registration Number: NCT02261727

Locations: 🇦🇺
The George Institute for Global Health, Sydney, New South Wales, Australia

Rituximab and Belimumab for Lupus Nephritis

Phase 2

Completed

Conditions: Lupus Nephritis

Interventions: Biological: Rituximab
Drug: Cyclophosphamide
Drug: Prednisone
Drug: Methylprednisolone
Drug: Diphenhydramine
Drug: Acetaminophen
Biological: Belimumab

First Posted Date: 2014-10-09

Last Posted Date: 2020-12-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 43

Registration Number: NCT02260934

Locations: 🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States
🇺🇸
UCLA Medical Center: Division of Rheumatology, Los Angeles, California, United States
🇺🇸
Colorado Kidney Care, Denver, Colorado, United States

and more 12 locations

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 3

Active, not recruiting

Conditions: Prostatic Neoplasms

Interventions: Drug: Apalutamide
Drug: Abiraterone acetate
Drug: Prednisone
Drug: Placebo

First Posted Date: 2014-10-06

Last Posted Date: 2024-12-20

Lead Sponsor: Aragon Pharmaceuticals, Inc.

Target Recruit Count: 982

Registration Number: NCT02257736

Dexamethasone Versus Prednisone in Heart Failure Patients, Hospitalized With Exacerbation of Chronic Obstructive Pulmonary Disease.

Phase 4

Recruiting

Conditions: Heart Failure
Chronic Obstructive Pulmonary Disease

Interventions: Drug: Dexamethasone
Drug: Prednisone

First Posted Date: 2014-09-11

Last Posted Date: 2023-04-06

Lead Sponsor: Rabin Medical Center

Target Recruit Count: 80

Registration Number: NCT02237820

Locations: 🇮🇱
Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Phase 1

Withdrawn

Conditions: Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease
Primary Effusion Lymphoma

Interventions: Drug: Pomalidomide
Drug: Rituximab
Drug: Prednisone
Drug: Etoposide
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide

First Posted Date: 2014-08-29

Last Posted Date: 2018-08-31

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT02228512

Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy

Phase 2

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Abiraterone acetate
Drug: Prednisone
Drug: Androgen deprivation therapy (ADT)

First Posted Date: 2014-08-15

Last Posted Date: 2020-01-13

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 46

Registration Number: NCT02217566

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Phase 1

Active, not recruiting

Conditions: Adult Grade III Lymphomatoid Granulomatosis
B-cell Chronic Lymphocytic Leukemia
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma
Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma
Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma
Contiguous Stage II Grade 1 Follicular Lymphoma
Contiguous Stage II Grade 2 Follicular Lymphoma
Contiguous Stage II Grade 3 Follicular Lymphoma
Contiguous Stage II Mantle Cell Lymphoma

Interventions: Drug: lenalidomide
Drug: etoposide
Drug: prednisone
Drug: vincristine sulfate
Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Biological: rituximab
Other: quality-of-life assessment
Other: laboratory biomarker analysis

First Posted Date: 2014-08-12

Last Posted Date: 2023-04-28

Lead Sponsor: University of Chicago

Target Recruit Count: 46

Registration Number: NCT02213913

Locations: 🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States
🇺🇸
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
🇺🇸
Illinois Cancer Care, Peoria, Illinois, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy